Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorUniversity of Florida
About this trial
Parkinsonism impairs upper airway and axial motor control, leading to disordered breathing, reduced speech volume, and ineffective cough. Symptoms are poorly addressed by current therapies. This randomized pilot trial tests whether a single session of acute intermittent hypercapnic hypoxia (AIHH) or hypercapnic normoxia (AIHN) improves upper airway and axial motor function in Parkinsonism, and explores biomarker correlates of intervention responsiveness.
Eligibility criteria
Qualifiers
adults 40 to 75 years of age (the latter to reduce the likelihood of cardiovascular disease)
diagnosis of idiopathic Parkinsonism with Hoehn and Yahr stages 2-4
medically stable with physician clearance
ability to ambulate at least 10 feet with/without assistance
Disqualifiers
additional neurologic conditions
severe illness or infection, including respiratory/cardiovascular/lung disease, or uncontrolled hypertension
inspiratory stridor
pregnancy due to unknown tAIH effects on a fetus, although females of childbearing age will not be excluded*
Trial design
Treatments tested in this trial
- Acute intermittent hypercapnic hypoxia (AIHH)
- Acute intermittent hypercapnic normoxia (AIHN)
Treatment groups
32 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov